June 1, 2017Open Access

Continuous Glucose Monitoring and Global Reimbursement: An Update

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Real-time continuous glucose monitoring has been available for a decade and reimbursement for the technology has been slowly growing. Reasons for the various rates of reimbursement and adoption are explored in this article and the status of country-wide reimbursement is discussed.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Claudia Graham (Thu,) studied this question.

synapsesocial.com/papers/6a0130e9581c6e761e77fed3 https://doi.org/https://doi.org/10.1089/dia.2017.0096

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial2012 · 492 citations
2Erratum. Glycemic Targets. Sec. 6. In<i>Standards of Medical Care in Diabetes—2017</i>. Diabetes Care 2017;40(Suppl. 1);S48–S562017 · 59 citations
3A Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension versus Standard Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes2014 · 43 citations
4Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data2011 · 539 citations
5Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective2015 · 41 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo